Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups prior to co-founding 1200 Pharma at the California Institute of Technology (Caltech, 2016).-Became the first employee of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures)-Remains an avid investor, focused on market trends and especially biotechnology stocks ...

Merck & Co., Inc. (MRK) announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication.The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Pleural mesothelioma is a type of cancer which develops in the tissue that lines the lungs or pleura.This is the first time Keytruda has been ...

Merck (MRK) announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer (NSCLC), met its primary endpoint of progression-free survival (PFS).The HERTHENA-Lung02 evaluated the efficacy and safety of patritumab deruxtecan versus pemetrexed and platinum chemotherapy for treating locally advanced or metastatic EGFR-mutated NSCLC in patients who had received prior EGFR tyrosine ki ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Merck (MRK) .Merck currently has an average brokerage recommendat ...

Merck & Co., Inc. (NYSE:MRK) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum - Head of Investor Relations Conference Call Participants Chen Yang - Bank of America Chen Yang Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations. My name is Charlie ...

Merck & Co., Inc. (NYSE:MRK) Bank of America Global Healthcare Conference September 18, 2024 6:40 AM ET Company Participants Joseph Romanelli - President, Human Health International Peter Dannenbaum - Head of Investor Relations Conference Call Participants Chen Yang - Bank of America Chen Yang Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations. My name is Charlie ...

This drugmaker faces a key test in the next several years.Merck (MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in this pharmaceutical giant's success is its Keytruda immunotherapy drug, recognized as a global standard of care for various cancers.On the other hand, investors must assess some uncertainty regarding the Keytruda platform, which could lose its patent exclusivity by the end of this decade, forcing Merck to find a new growth driver. ...

JHVEPhoto In late July, Merck experienced a sharp, 15% decline following what appeared to be a five month distribution top. Many investors now believe Merck is going lower, but we don’t, at least not yet. The technical and sentiment indicators we follow suggest Merck is ready for a year-end rally that will carry it back to previous highs. If it does it will provide current holders a second opportunity to reassess the situation and either sell or hold for higher prices. It would also provide new buyers w ...

Merck (MRK) closed at $115.86 in the latest trading session, marking a +0.53% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.54% for the day. Meanwhile, the Dow gained 0.72%, and the Nasdaq, a tech-heavy index, added 0.65%.Shares of the pharmaceutical company have appreciated by 1.71% over the course of the past month, underperforming the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86%.The investment community will be closely monitoring the performa ...

Merck’s (MRK) stock declined 2% on Monday after Summit Therapeutics’ (SMMT) investigational bispecific antibody, ivonescimab, outperformed Merck’s blockbuster PD-L1 inhibitor Keytruda in a first-line lung cancer study.SMMT’s Ivonescimab Shows Meaningful Benefit Over MRK’s KeytrudaThe phase III HARMONi-2 study evaluated ivonescimab monotherapy against Keytruda monotherapy as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC). The study was conducted in China with Summit’s c ...